Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib

Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental fa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Englinger, Bernhard, Laemmerer, Anna, Moser, Patrick, Kallus, Sebastian, Röhrl, Clemens, Pirker, Christine, Baier, Dina, Mohr, Thomas, Niederstaetter, Laura, Meier‐Menches, Samuel M., Gerner, Christopher, Gabler, Lisa, Gojo, Johannes, Timelthaler, Gerald, Senkiv, Julia, Jäger, Walter, Kowol, Christian R., Heffeter, Petra, Berger, Walter
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Cancer Therapy and Prevention
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497038/
https://ncbi.nlm.nih.gov/pubmed/32064608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32924
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars